Posted in Regulatory Travere Therapeutics gains FDA approval for sparsentan in FSGS April 14, 2026 Pharmaceutical Business Review The approval makes Filspari the first and only FDA-approved medicine to treat FSGS, expanding its use beyond IgA nephropathy (IgAN) into a second rare kidney condition. RegulatoryRare DiseaseRead full story